Gilead to buy CymaBay Therapeutics for $4.3B



California-based pharmaceutical giant Gilead Sciences disclosed on Monday that it will acquire CymaBay Therapeutics Inc. for an estimated $4.3 billion or $32.50 per share. The transaction is anticipat…
About the author:

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento